Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference
Cabaletta Bio, a clinical-stage biotech firm specializing in curative targeted cell therapies for autoimmune diseases, announced its CEO, Steven Nichtberger, will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 5, 2024. The event will be held at 11:00 a.m. ET in New York, NY. A live webcast of the presentation will be accessible on Cabaletta Bio's website, with replays available for 30 days.
- Cabaletta Bio's participation in a major healthcare conference could boost visibility and credibility.
- Live webcast allows for broader investor access to the presentation.
- Focus on curative targeted cell therapies for autoimmune diseases positions the company in a potentially lucrative market.
- No concrete financial or clinical data updates were provided in the announcement.
- The announcement does not mention any new partnerships or business developments.
PHILADELPHIA, May 29, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that Steven Nichtberger, M.D., Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024, at 11:00 a.m. ET in New York, NY.
A live webcast of the presentation will be available on the News and Events section of the Company’s website at www.cabalettabio.com. Replays will be available on the website for 30 days.
About Cabaletta Bio
Cabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies that have the potential to provide a deep and durable, perhaps curative, treatment for patients with autoimmune diseases. The CABA™ platform encompasses two strategies: the CARTA (chimeric antigen receptor T cells for autoimmunity) strategy, with CABA-201, a 4-1BB-containing fully human CD19-CAR T, as the lead product candidate being evaluated in the RESET™ (REstoring SElf-Tolerance) clinical trials in systemic lupus erythematosus, myositis, systemic sclerosis and generalized myasthenia gravis and in the RESET-PV™ sub-study within the DesCAARTes™ clinical trial in pemphigus vulgaris, along with the CAART (chimeric autoantibody receptor T cells) strategy, with multiple clinical-stage candidates, including DSG3-CAART for mucosal pemphigus vulgaris and MuSK-CAART for MuSK-associated myasthenia gravis. The expanding CABA™ platform is designed to develop potentially curative therapies that offer deep and durable responses for patients with a broad range of autoimmune diseases. Cabaletta Bio’s headquarters and labs are located in Philadelphia, PA.
Contacts:
Anup Marda
Chief Financial Officer
investors@cabalettabio.com
William Gramig
Precision AQ
william.gramig@precisionaq.com
FAQ
When will Cabaletta Bio participate in the Jefferies Global Healthcare Conference?
What kind of therapies is Cabaletta Bio developing?
Where can I watch the live webcast of Cabaletta Bio's presentation?
How long will the replay of the webcast be available?
What is the stock symbol for Cabaletta Bio?
